High-throughput characterization of virus-like particles by interlaced size-exclusion chromatography

Effio, Christopher Ladd; Oelmeier, Stefan A.; Hubbuch, Jürgen

doi:10.1016/j.vaccine.2016.01.035

Cited by 28 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our efforts to purify HCoV-NL63 VLPs using this method failed. Most of the alternative purification methods are based on size-exclusion column purification [60][61][62]. A limitation of this approach is that a relatively low amount of material can be loaded onto a size-exclusion column.…”

Section: Discussionmentioning

confidence: 99%

Novel coronavirus-like particles targeting cells lining the respiratory tract

et al. 2018

View full text Add to dashboard Cite

Virus like particles (VLPs) produced by the expression of viral structural proteins can serve as versatile nanovectors or potential vaccine candidates. In this study we describe for the first time the generation of HCoV-NL63 VLPs using baculovirus system. Major structural proteins of HCoV-NL63 have been expressed in tagged or native form, and their assembly to form VLPs was evaluated. Additionally, a novel procedure for chromatography purification of HCoV-NL63 VLPs was developed. Interestingly, we show that these nanoparticles may deliver cargo and selectively transduce cells expressing the ACE2 protein such as ciliated cells of the respiratory tract. Production of a specific delivery vector is a major challenge for research concerning targeting molecules. The obtained results show that HCoV-NL63 VLPs may be efficiently produced, purified, modified and serve as a delivery platform. This study constitutes an important basis for further development of a promising viral vector displaying narrow tissue tropism.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel coronavirus-like particles targeting cells lining the respiratory tract

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A number of culture-independent methods exist now to characterize the novel viruses and their genes. Biochemical assays for RdRp, proteases, helicases, capsids, and internal ribosome entry sites all exist and synthetic biology allows for easy cloning from a database to test these new proteins found through metagenomics (Ladd Effio et al, 2016;O'Donoghue et al, 2012;Peersen, 2017). Profiling known functions across the new viral species, such as RNA binding strength and sequence specificity of novel RNA phage proteins related to MS2 phage or viral protease specificity and kinetics, might be a place to start (O'Donoghue et al, 2012).…”

Section: Experimenting With Functionmentioning

confidence: 99%

A decade of RNA virus metagenomics is (not) enough

2018

View full text Add to dashboard Cite

It is hard to overemphasize the role that metagenomics has had on our recent understanding of RNA virus diversity. Metagenomics in the 21st century has brought with it an explosion in the number of RNA virus species, genera, and families far exceeding that following the discovery of the microscope in the 18th century for eukaryotic life or culture media in the 19th century for bacteriology or the 20th century for virology. When the definition of success in organism discovery is measured by sequence diversity and evolutionary distance, RNA viruses win. This review explores the history of RNA virus metagenomics, reasons for the successes so far in RNA virus metagenomics, and methodological concerns. In addition, the review briefly covers clinical metagenomics and environmental metagenomics and highlights some of the critical accomplishments that have defined the fast pace of RNA virus discoveries in recent years. Slightly more than a decade in, the field is exhausted from its discoveries but knows that there is yet even more out there to be found.

show abstract

“…Tekewe et al () developed a high throughput method based upon dynamic light scattering technology that permits rapid analysis of capsomere stability based on their hydrodynamic radius. A size exclusion ultrahigh performance liquid chromatography method was also developed in which VLP samples were analyzed in 3.1 min using an interlaced injection technique, allowing accurate quantitation of VLP aggregates (Effio, Oelmeier, & Hubbuch, ). More recently, a universal label‐free analytical tool for influenza VLPs quantification based on biolayer interferometry technology applied on an octet platform was developed (Carvalho, Moleirinho, et al, 2017).…”

Section: Considerations For Vlp Productionmentioning

confidence: 99%

Synthetic biology for bioengineering virus‐like particle vaccines

Hume

Vidigal

Carrondo

et al. 2018

Biotech & Bioengineering

View full text Add to dashboard Cite

Vaccination is the most effective method of disease prevention and control. Many viruses and bacteria that once caused catastrophic pandemics (e.g., smallpox, poliomyelitis, measles, and diphtheria) are either eradicated or effectively controlled through routine vaccination programs. Nonetheless, vaccine manufacturing remains incredibly challenging. Viruses exhibiting high antigenic diversity and high mutation rates cannot be fairly contested using traditional vaccine production methods and complexities surrounding the manufacturing processes, which impose significant limitations. Virus-like particles (VLPs) are recombinantly produced viral structures that exhibit immunoprotective traits of native viruses but are noninfectious. SeveralVLPs that compositionally match a given natural virus have been developed and licensed as vaccines. Expansively, a plethora of studies now confirms that VLPs can be designed to safely present heterologous antigens from a variety of pathogens unrelated to the chosen carrier VLPs. Owing to this design versatility, VLPs offer technological opportunities to modernize vaccine supply and disease response through rational bioengineering. These opportunities are greatly enhanced with the application of synthetic biology, the redesign and construction of novel biological entities. This review outlines how synthetic biology is currently applied to engineer VLP functions and manufacturing process. Current and developing technologies for the identification of novel target-specific antigens and their usefulness for rational engineering of VLP functions (e.g., presentation of structurally diverse antigens, enhanced antigen immunogenicity, and improved vaccine stability) are described.When applied to manufacturing processes, synthetic biology approaches can also overcome specific challenges in VLP vaccine production. Finally, we address several challenges and benefits associated with the translation of VLP vaccine development into the industry. K E Y W O R D S

show abstract

High-throughput characterization of virus-like particles by interlaced size-exclusion chromatography

Cited by 28 publications

References 42 publications

Novel coronavirus-like particles targeting cells lining the respiratory tract

Novel coronavirus-like particles targeting cells lining the respiratory tract

A decade of RNA virus metagenomics is (not) enough

Synthetic biology for bioengineering virus‐like particle vaccines

Contact Info

Product

Resources

About